Guardant Health, ConcertAI Collaborate to Form First Data-As-A-Service That Integrates Clinical and Tumor Profiling Data to Accelerate Cancer Therapy Research and Development (Guardant Health)

Guardant Health and ConcertAI have partnered to create a first-of-its-kind multi-modal real-world data (RWD) solution, integrating comprehensive patient EMR data with genomic and epigenomic tumor profiling. By combining Guardant’s liquid biopsy technology with ConcertAI’s AI-driven analytics, the collaboration aims to provide biopharma companies with deeper insights into cancer biology, resistance mechanisms, and tumor evolution across the cancer care continuum. This innovative approach includes unique methylation data from Guardant’s platform and is expected to enhance cancer therapy development, clinical trial design, and precision medicine strategies. Financial terms of the agreement remain undisclosed.